Cyclophosphamide: uses, dosing, side effects & brands

Cyclophosphamide is a medicine sold in the U.S. under 5 brand and generic names, for autoimmune hemolytic anemia, breast neoplasms and burkitt lymphoma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesUpdated Jul 24, 2026How we research

Key facts

Treats (across its forms): Autoimmune Hemolytic Anemia, Breast Neoplasms and Burkitt Lymphoma
Available as: Injectable · Powder · Capsule · Solution · Tablet
Sold as: 5 products — Cyclophosphamide, Cytoxan and Cytoxan (Lyophilized), and others
Prescription?: Prescription only
Generic available?: Yes
What the pharmacy pays: about $40 for a 30-count supply — not your price

How Cytoxan is dosed

From the FDA label for Cytoxan (application NDA012141). Other cyclophosphamide products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

During or immediately after the administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity ( 2.1 ). Malignant Diseases: Adult and Pediatric Patients • Oral: Usually 1 mg per kg to 5 mg per kg once daily for both initial and maintenance dosing. ( 2.2 ) Minimal Change Nephrotic Syndrome in Pediatric Patients • Recommended oral dose: 2 mg per kg once daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg). Treatment beyond 90 days increases the probability of sterility in males. ( 2.3 ) 2.1 Hydration and Important Administration Instructions During or immediately after the administration of Cyclophosphamide Tablets, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, Cyclophosphamide Tablets should be taken in the morning. Cyclophosphamide Tablets should be swallowed whole. The tablets should not be chewed or crushed. Cyclophosphamide Tablets is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Exposure to broken tablets should be avoided. If contact with broken tablets occurs, wash hands immediately and thoroughly. 2.2 Recommended Dosage for Malignant Diseases Adults and Pediatric Patients The recommended dose of Cyclophosphamide Tablets is in the range of 1 mg per kg to 5 mg per kg orally once daily for both initial…

Everything below is the FDA label for Cytoxan (tablet). Cyclophosphamide is also sold as injectable, powder, capsule and solution, and those are different medicines to take — follow the label for the one you were prescribed.

Cytoxan side effects

The following adverse reactions are discussed in more detail in other sections of the labeling. • Hypersensitivity [see Contraindications (4) ] • Myelosuppression, Immunosuppression, Bone Marrow Failure, and Infections [see Warnings and Precautions (5.1) ] • Urinary Tract and Renal Toxicity [see Warnings and Precautions (5.2) ] • Cardiotoxicity [see Warnings and Precautions (5.3) ] • Pulmonary Toxicity [see Warnings and Precautions (5.4) ] • Secondary Malignancies [see Warnings and Precautions (5.5) ] • Veno-occlusive Liver Disease [see Warnings and Precautions (5.6) ] • Infertility [see Warnings and Precautions (5.8) and Use in Specific Populations (8.3 , 8.4) ] • Impaired Wound Healing [see Warnings and Precautions (5.9) ] • Hyponatremia [see Warnings and Precautions (5.10) ] Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Common Adverse Reactions Hematopoietic system: Neutropenia occurs in patients treated with cyclophosphamide. The degree of neutropenia is particularly important because it correlates with a reduction in resistance to infections. Fever without documented infection has been reported in neutropenic patients. Gastrointestinal system: Nausea…

Who shouldn’t take Cytoxan

Cyclophosphamide Tablets are contraindicated in patients with: • A history of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Cross-sensitivity with other alkylating agents can occur. • In patients with urinary outflow obstruction [see Warnings and Precautions (5.2) ]. • Hypersensitivity to cyclophosphamide (4) • Urinary outflow obstruction (4)

Cytoxan drug interactions

Cyclophosphamide is a pro-drug that is activated by cytochrome P450s [see Clinical Pharmacology (12.3) ]. An increase of the concentration of cytotoxic metabolites may occur with: • Protease inhibitors: Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites. Use of protease inhibitor-based regimens was found to be associated with a higher Incidence of infections and neutropenia in patients receiving cyclophosphamide, doxorubicin, and etoposide (CDE) than use of a Non-Nucleoside Reverse Transcriptase Inhibitor-based regimen. Combined or sequential use of cyclophosphamide and other agents with similar toxicities can potentiate toxicities. • Increased hematotoxicity and/or immunosuppression may result from a combined effect of cyclophosphamide and, for example: o ACE inhibitors: ACE inhibitors can cause leukopenia. o Natalizumab Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. Thiazide diuretics Zidovudine Increased cardiotoxicity may result from a combined effect of cyclophosphamide and, for example: • Anthracyclines • Cytarabine • Pentostatin • Radiation therapy of the cardiac region • Trastuzumab • Increased pulmonary toxicity may result from a combined effect of cyclophosphamide and, for example: • Amiodarone • G-CSF, GM-CSF (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor): Reports suggest an increased risk of pulmonary toxicity in patients treated with cytotoxic chemotherapy that includes cyclophosphamide and G-CSF or GMCSF. • Increased nephrotoxicity may result from a combined effect of cyclophosphamide and, for example: Amphotericin B Indomethacin: Acute water intoxication has been reported with concomitant use of indomethacin Increase in other toxicities: Azathioprine: Increased risk of hepatotoxicity (liver necrosis) Busulfan: Increased incidence of hepatic veno-occlusive disease and mucositis has been reported. Protease inhibitors: Increased incidence of mucositis Increased risk of hemorrhagic cystitis may result from a combined effect of cyclophosphamide and past or concomitant radiation treatment. Etanercept: In patients with Wegener’s granulomatosis, the addition of etanercept to standard treatment, including cyclophosphamide, was associated with a higher incidence of non-cutaneous malignant solid tumors. Metronidazole: Acute encephalopathy has been reported in a patient receiving cyclophosphamide and metronidazole. Causal association is unclear. In an animal study, the combination of cyclophosphamide with metronidazole was associated with increased cyclophosphamide toxicity. Tamoxifen: Concomitant use of tamoxifen and chemotherapy may increase the risk of thromboembolic complications. Coumarins: Both increased and decreased warfarin effect have been reported in patients receiving warfarin and cyclophosphamide. Cyclosporine: Lower serum concentrations of cyclosporine have been observed in patients receiving a combination of cyclophosphamide and cyclosporine than in patients receiving only cyclosporine. This interaction may result in an increased incidence of graft-versus-host disease. Depolarizing muscle relaxants: Cyclophosphamide treatment causes a marked and persistent inhibition of cholinesterase activity. Prolonged apnea may occur with concurrent depolarizing muscle relaxants (e.g., succinylcholine). If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, alert the anesthesiologist.

Every cyclophosphamide product we track (5)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Cyclophosphamide products
#	Drug	Rating	Type	Form	Generic?	Pharmacy pays
1	Cyclophosphamide	70/100	Prescription	Injectable	Generic	$40	View →
2	Cytoxan	Not yet rated	Prescription	Tablet	Generic	$40	View →
3	Cytoxan (Lyophilized)	Not yet rated	Prescription	Injectable	Generic	$40	View →
4	Frindovyx	Not yet rated	Prescription	Injectable	Generic	$40	View →
5	Lyophilized Cytoxan	Not yet rated	Prescription	Injectable	Generic	$40	View →

What cyclophosphamide pills look like

Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.

Cyclophosphamide pill imprints
Imprint	Strength	Colour	Shape	Maker
BXT;25	25 mg	white	round	—
BXT;50	50 mg	white	round	—

Cyclophosphamide recalls

From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.

Can you crush or split cyclophosphamide?

At least one cyclophosphamideproduct is labelled to be swallowed whole — crushing an extended-release tablet releases the whole day’s dose at once. Which applies depends on the form you were given.

What each cyclophosphamide label says about crushing, splitting and chewing

How long cyclophosphamide keeps

The date on a sealed pack is not the only one: some cyclophosphamide labels start a second clock once the product is opened or mixed, as short as 14 days.

Does cyclophosphamide expire? The in-use limits and storage rules from its labels

Cyclophosphamide and breastfeeding

From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.

Cyclophosphamide appears in milk in potentially toxic amounts; additionally, highly toxic active metabolites could add to the risk to the infant. Neutropenia has been reported in 2 infants whose mothers breastfed them while receiving cyclophosphamide. Most sources consider breastfeeding to be contraindicated during maternal cytotoxic antineoplastic drug therapy, especially alkylating agents such as cyclophosphamide. Although some authors have suggested withholding breastfeeding for 1 to 3 days after a dose, the manufacturer recommends waiting for 1 week after the last dose before resuming breastfeeding.

Full LactMed record for cyclophosphamide: levels in milk, effects in breastfed infants, and the drugs it would consider instead

National Institute of Child Health and Human Development, record revised September 15, 2025. LactMed states its information is not a substitute for professional judgement.

What people report to the FDA about cyclophosphamide

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 183,679 reports naming cyclophosphamide, and the FDA flagged 96% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

febrile neutropenia15,004 reports
neutropenia10,822 reports
pyrexia9,442 reports
pneumonia6,789 reports
thrombocytopenia6,635 reports
nausea6,412 reports
anaemia6,223 reports
sepsis5,880 reports

Read these as a signal, not a rate. A report does not mean cyclophosphamide caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.

Source: openFDA drug/event (FAERS), retrieved July 25, 2026.

Related calculators

How long it stays in your system →

Frequently asked questions

What is Cytoxan?

Cytoxan (Cyclophosphamide) is a medication used to treat Autoimmune Hemolytic Anemia, Breast Neoplasms, Burkitt Lymphoma, Hemosiderosis.

Can you take cyclophosphamide with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run cyclophosphamide against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What brand names is cyclophosphamide sold under?

We track 5 cyclophosphamide-containing products in the U.S.: Cyclophosphamide, Cytoxan, Cytoxan (Lyophilized), Frindovyx and Lyophilized Cytoxan. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

What forms does cyclophosphamide come in?

Across the brands we track, cyclophosphamide is currently marketed as injectable, powder, capsule, solution and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic cyclophosphamide?

Yes. Our catalog lists 1 generic cyclophosphamide product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

Has cyclophosphamide been recalled?

The FDA's Enforcement database lists at least 5 recall records whose product description mentions cyclophosphamide. The most recent: Cyclophosphamide for Injection (Jul 17, 2026). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Cite this page

APA: pharmaranks. (2026, July 24). Cyclophosphamide: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/cyclophosphamide
MLA: “Cyclophosphamide: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/cyclophosphamide.

We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.

Read the full FDA label for cyclophosphamide on DailyMed (NIH) ↗.